Clinical Trials

50 enrolled

Carcinoma, Hepatocellular

NCT07521852 2026-04-13

A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC

40 enrolled

Carcinoma, Hepatocellular, Neoplasms

NCT07506109 2026-04-07

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

49 enrolled

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT07515625 2026-04-07

Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma

46 enrolled

Stomach Neoplasms

NCT07509424 2026-04-03

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

29 enrolled

Rectal Neoplasms

NCT04512534 2026-04-02

Sincerely20

51 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT04877821 2026-04-02

NeoSACT

29 enrolled

Triple Negative Breast Neoplasms

NCT07331883 2026-03-27

Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)

35 enrolled

Carcinoma, Hepatocellular

NCT07492342 2026-03-25

K-NADIR

Resectable NSCLC

NCT07492615 2026-03-25

A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma

276 enrolled

Stomach Neoplasms

NCT07394387 2026-03-19

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

39 enrolled

Triple Negative Breast Neoplasms

NCT07468630 2026-03-12

TRIUNITE-08

106 enrolled

Colonic Neoplasms

NCT05024968 2026-02-25

Sintilimab in Cancer of Unknown Primary

10 enrolled 9 charts

Tumor-Agnostic

Neoplasms, Unknown Primary

NCT07398326 2026-02-09

Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer

37 enrolled

Phase 2 Active not recruiting

Colorectal Neoplasms

NCT07005336 2026-01-30

A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer

150 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07077512 2026-01-21

Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT07351487 2026-01-20

Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)

37 enrolled

Triple Negative Breast Neoplasms

NCT05348811 2026-01-06

HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

25 enrolled

Cholangiocarcinoma

NCT07120698 2026-01-05

CTONG 2508

115 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07309952 2025-12-30

SACTION 2501

28 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05472948 2025-12-17

Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

36 enrolled

Appendiceal Neoplasms, Neoplasm Metastasis

NCT06121505 2025-12-17

Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer

114 enrolled

Lung Squamous Cell Carcinoma

NCT07179900 2025-12-11

Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

60 enrolled

Carcinoma, Hepatocellular

NCT07263386 2025-12-04

ARTEMIS-GC3

460 enrolled

Gastric Adenocarcinoma

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

300 enrolled

Carcinoma, Hepatocellular

NCT07254858 2025-11-28

CISN-L

302 enrolled

Breast Neoplasms

NCT06493240 2025-11-25

NLCCRIT-LARC

Phase 2 Active not recruiting

Locally Advanced Rectal Cancer

NCT05177068 2025-10-02

Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer

42 enrolled

Stomach Neoplasms

NCT07194005 2025-09-26

Remission

Stomach Neoplasms

NCT07088731 2025-09-22

Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer

180 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT06577194 2025-09-19

A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer

35 enrolled

Phase 2 Active not recruiting

Rectal Neoplasms

NCT05481476 2025-09-04

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

32 enrolled

Pancreatic Neoplasms

NCT05026736 2025-08-17

Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study

Phase 2 Terminated

6 enrolled

Sarcoma

Hemangiosarcoma

NCT06031285 2025-07-23

Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial

43 enrolled

Carcinoma, Hepatocellular

NCT06050317 2025-07-22

Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

25 enrolled

Pancreatic Neoplasms

NCT07061535 2025-07-11

STAR-SCLC

40 enrolled

Small Cell Lung Carcinoma

NCT07053150 2025-07-08

CCGLC-018

80 enrolled

Advanced Digestive System Tumor

NCT06356584 2025-06-26

Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

62 enrolled

Colorectal Neoplasms

NCT07040098 2025-06-26

STELLARIII

228 enrolled

Locally Advanced Rectal Cancer (LARC)

NCT05161572 2025-06-18

NeoRacing

Phase 2 Terminated

6 enrolled

Adenocarcinoma, Stomach Neoplasms

NCT06013618 2025-06-17

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

120 enrolled

CNS

Neuroblastoma

NCT04548440 2025-06-12

Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients

50 enrolled

Esophageal Squamous Cell Carcinoma

NCT07018063 2025-06-12

YOUNG-NEOS

35 enrolled

Neoplasms, Stomach Neoplasms

NCT07007767 2025-06-06

Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）

32 enrolled